- Home
- STTK vs DHAI Comparison
STTK vs DHAI Comparison
Compare STTK & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- DHAI
- Stock Information
- Founded
- STTK 2016
- DHAI 2007
- Country
- STTK United States
- DHAI United States
- Employees
- STTK N/A
- DHAI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- DHAI
- Sector
- STTK Health Care
- DHAI
- Exchange
- STTK Nasdaq
- DHAI NYSE
- Market Cap
- STTK 56.8M
- DHAI 49.1M
- IPO Year
- STTK 2020
- DHAI N/A
- Fundamental
- Price
- STTK $1.37
- DHAI $0.49
- Analyst Decision
- STTK Hold
- DHAI
- Analyst Count
- STTK 3
- DHAI 0
- Target Price
- STTK $2.00
- DHAI N/A
- AVG Volume (30 Days)
- STTK 131.9K
- DHAI 310.5K
- Earning Date
- STTK 03-03-2025
- DHAI 02-14-2025
- Dividend Yield
- STTK N/A
- DHAI N/A
- EPS Growth
- STTK N/A
- DHAI N/A
- EPS
- STTK N/A
- DHAI N/A
- Revenue
- STTK $6,435,000.00
- DHAI $69,573,000.00
- Revenue This Year
- STTK $313.04
- DHAI N/A
- Revenue Next Year
- STTK N/A
- DHAI N/A
- P/E Ratio
- STTK N/A
- DHAI N/A
- Revenue Growth
- STTK 382.75
- DHAI 5.40
- 52 Week Low
- STTK $0.94
- DHAI $0.48
- 52 Week High
- STTK $11.76
- DHAI $3.67
- Technical
- Relative Strength Index (RSI)
- STTK 60.23
- DHAI 31.78
- Support Level
- STTK $1.21
- DHAI $0.48
- Resistance Level
- STTK $1.36
- DHAI $0.69
- Average True Range (ATR)
- STTK 0.10
- DHAI 0.09
- MACD
- STTK 0.01
- DHAI -0.00
- Stochastic Oscillator
- STTK 90.00
- DHAI 4.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.